ArticleNPJ precision oncology2026
ShinyEvents: harmonizing longitudinal data for real-world survival estimation.
Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A dual-phase strategy to integrate the VITEK MS RUO database into routine clinical practice: from validation of analytical performance to implementation of an automated workflow.Frontiers in cellular and infection microbiology · 2026Article
Corrections and comments
- Update of
Authors and funding
22 authors.
Funding
Abstract
Longitudinal data analysis of the patient's treatment course is critical to uncovering variables that influence outcomes. However, existing tools have significant limitations in integrating multilayered time-series data, particularly in linking treatment events with survival outcomes. Here, we developed ShinyEvents, a web-based framework for complex longitudinal data analysis. ShinyEvents allows users to upload data and generate interactive timelines of clinical events, enabling cohort-level analyses such as treatment clustering and endpoint assignment. It also provides informative cohort visualizations, such as a Sankey diagram of the treatment line and a Swimmer diagram of the clinical course. Finally, our tool can infer real-world progression-free survival (rwPFS) based on user-defined endpoints and perform Kaplan-Meier and Cox proportional hazards regression analysis. With these features, the tool can then associate treatment lines with clinical outcomes. As a case study, we analyzed Moffitt patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy followed by surgery. Patients treated with cisplatin and gemcitabine exhibited more favorable rwPFS and overall survival, which is consistent with prior reports. Altogether, ShinyEvents provides a unified framework for integrating longitudinal real-world data with survival analytics, fostering transparent and reproducible collaboration between clinicians and data scientists. A live demo is available at https://shawlab-moffitt.shinyapps.io/shinyevents/ .
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.